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F o r P e e r R e v i e w induced mechanical hypersensitivity was ameliorated by MitoVitE treatment to a similar extent as duloxetine. These data confirm mitochondria as a mechanistic target for paclitaxelinduced damage and suggest mitochondria targeted antioxidants as future therapeutic strategies.
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MitoVitE limits paclitaxel-induced damage and mechanical hypersensitivity 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w Chemotherapy induced peripheral neuropathy (CIPN) is a common and severe adverse effect of some commonly used chemotherapeutic drugs, including paclitaxel. The severity of symptoms can require a dose reduction, or even cessation of chemotherapy, impacting on survival. CIPN affects around 33% of patients, and can persist months or years beyond the cessation of treatment. It is characterized by numbness, paresthesia, and pain. 1 2 Duloxetine is the only treatment which has been shown in a randomized clinical trial to be effective in some patients with CIPN 3 and is recommended as a first line treatment for adults with this condition. However, long term management of CIPN is often inadequate and there is urgent need for a mechanism-derived novel treatment. 4 Mitochondria produce most of the body's cellular energy via oxidative phosphorylation, producing reactive oxygen species (ROS) in the process. Although ROS are potentially toxic, they have essential roles in cell signalling and any damage is controlled by an interacting and highly regulated system of endogenous antioxidants. As well as being the main source of ROS, mitochondria are also a target for damage and when antioxidant defences are overwhelmed, oxidative stress can result in mitochondrial dysfunction and impairment of ATP production. Thus damage to mitochondria is caused primarily by ROS produced by the mitochondria themselves. 5 Paclitaxel has been shown to cause oxidative stress and mitochondrial damage [6] [7] and accumulates in neuronal tissue. Neuronal cells are particularly sensitive to oxidative insults, and ROS have been implicated in many neurodegenerative processes, including Alzheimer's,
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Parkinson's, and Huntington's diseases, acute brain ischaemia, and excitotoxicity.
Neuropathic pain as a result of paclitaxel therapy may be related to mitochondrial damage to neuronal cells [8] [9] and so antioxidants which are able to protect inside mitochondria may be useful. Antioxidants can be targeted selectively to mitochondria by conjugation to a lipophilic cation. 10 MitoVitE consists of α-tocopherol attached to a triphenylphosphonium (TPP) cation, enabling its rapid uptake through the plasma and mitochondrial membranes and accumulation within mitochondria as a result of the large membrane potential (negative inside) across the mitochondrial inner membrane. MitoVitE accumulates in all major organs of mice and rats after oral, intraperitoneal (i.p.) or intravenous administration. 11 Trolox (6-hydroxy-2,5,7,8-tetra methylchroman-2-carboxylic acid) is a synthetic, water soluble cellpermeable derivative of vitamin E which accumulates in the cell cytosol and has potent antioxidant activity with direct scavenging activity against peroxyl and alkoxyl radicals. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w The aim of this study was to investigate the effects of two vitamin E-based antioxidants in an in vitro model of paclitaxel-induced oxidative stress and mitochondrial damage in a DRG cell line, and effects on mechanical hypersensitivity in a preclinical model of paclitaxel CIPN in rats.
Materials and methods

In vitro studies
An immortalized dorsal root ganglion (DRG) neuronal stem cell line (50B11) with nociceptive properties was used (a kind gift from Professor Ahmet Hoke, from Johns Hopkins School of glutamine, 50µg/ml gentamycin, 250µg/ml amphotericin-B and 5µg/ml ciprofloxacin, in a humidified incubator containing 5% CO 2 at 37°C. Cells were then treated with 75µM forskolin and allowed to differentiate into DRG for 24h. Neurite outgrowth normally started around 10 hours after addition of forskolin. After 24h exposure to forskolin, paclitaxel (0-100µM) was added, corresponding broadly to levels seen in the circulation during clinical use. However, paclitaxel accumulates in cells and tissues and so the concentration range was extended to allow for this. In addition some cells were also concurrently exposed to 1µM MitoVitE, 1µM
Trolox or a relevant solvent control.
Acid phosphatase activity
Acid phosphatase activity was used to assess cell viability. 15 Differentiated cells were grown in 96-well plates and treated as described above for 24h then washed twice with phosphate buffered saline (PBS). Acid phosphatase solution containing 0.1M sodium acetate, 1% v/v Triton X-100, 5mM p-nitrophenyl in distilled water (pH 5.0) was added to each well and cells were incubated in the dark for 1h at 37°C. Sodium hydroxide (0.25M) was added to stop the reaction and the absorbance measured using a spectrophotometer at 450nm.
Mitochondrial function
Mitochondrial membrane potential was analyzed in intact cells using the fluorescent probe 
Glutathione (GSH)
Cellular GSH levels were measured as an indicator of oxidative stress. The lipophilic compound monochlorobrimane (MCB, Sigma, Dorset, UK) binds to GSH via the action of the enzyme glutathione-S-transferase. The fluorescence of the resulting MCB-GSH conjugate is proportional to cellular GSH concentration. 18 Cells were treated for 24h as above, washed with PBS and incubated with 20µM MCB for 30 minutes at 37°C. GSH was analysed by measuring fluorescence at excitation/emission wavelengths of 340/520nm. Results were corrected for cell viability.
Cancer cell cytotoxicity
Since it is possible that antioxidants would either interfere with or enhance the ability of paclitaxel to kill cancer cells, we also conducted experiments using the breast adenocarcinoma-like oestrogen-sensitive cell line, MCF-7, and the ovarian carcinoma cell line A2780, to assess paclitaxel induced cell killing in the presence of the antioxidants. Cells were cultured in Dulbecco's modification of Eagle's medium (DMEM) supplemented with 4.5g/l glucose, 10% v/v foetal calf serum, 50µg/ml gentamycin and 250µg/ml amphotericin-B for 24h. Cell viability was measured using acid phosphatase activity as described above. For behavioural sensory testing, rats were acclimatised to testing apparatus in 2 x 20 min sessions on separate days prior to testing, and further habituated for 20 min immediately prior to testing on any given day. To ensure blinding of the tester to the treatment, rats from several cages were briefly combined in a single cage before testing commenced; group allocation was only confirmed by tail number after testing was complete. Mechanical withdrawal thresholds were measured using the up-down method using a series of von Frey filaments of varying weights to gauge the withdrawal threshold and thereby mechanical sensitivity. 20 Starting with a 2g filament, increasingly heavier filaments were applied to the plantar region of the hind paw until a paw withdrawal response was observed. Sequentially smaller filaments were then tested until no response was observed, then increased again until a response was observed. This approach was repeated until there were five measures after the initial response. The value of the final filament tested, and sequence of responses were then used to calculate the mechanical threshold using the equation devised by Chaplan et al. 20 Behavioural measures were undertaken 3, 6 and 9 h after the MitoVitE or duloxetine injection, every 2 d starting 3 d before paclitaxel administration and continuing until 14 d after initial paclitaxel administration.
Animal model
Statistical analysis
For in vitro studies, 6 independent experiments with 4 technical replicates were undertaken 
Mitochondrial function
Exposure of cells to paclitaxel at all doses without antioxidants resulted in decreased JC-1 red/green fluorescence ratio, indicating a loss of mitochondrial membrane potential (p<0.0001, Fig 1A) . Mitochondrial membrane potential in cells without paclitaxel was similar to cells with antioxidant only, but in cells co-treated with paclitaxel and MitoVitE, membrane potential was only decreased at the highest dose of paclitaxel ( Fig 1A) . Cells treated with Trolox had similar loss of membrane potential to paclitaxel alone (Fig 1A) , suggesting that it was ineffective at preventing loss of potential induced by paclitaxel. Mitochondrial metabolic activity was significantly lower in cells treated with paclitaxel regardless of dose (p<0.0001, Fig 1B) . In cells co-treated with MitoVitE there was no decrease in metabolic activity even at the highest paclitaxel dose (Fig 1B) . Trolox in contrast, worsened the loss of metabolic activity (Fig 1B) .
Glutathione (GSH)
Compared to control treatments, cellular GSH levels were significantly lower in cells exposed to paclitaxel without antioxidants, independent of the paclitaxel dose (p<0.0001, Fig 1C) . Coexposure of paclitaxel with MitoVitE but not Trolox, mitigated the effect on GSH (Fig 1C) .
Cancer cell cytotoxicity
Exposure of the A2780 ovarian carcinoma cell line or the MCF7 breast adenoma cell line to paclitaxel resulted in dose-dependent decreases in acid phosphatase activity, indicating loss of cell viability, such that at 100µM paclitaxel, only 60% of cells were viable. Co-exposure of cells to paclitaxel plus MitoVitE showed similar loss of viability (Figs 2A and 2B) . Similar results were seen in Trolox treated ovarian cancer cells (Fig 2A) , but paclitaxel mediated killing of breast cancer cells was less effective in the presence of Trolox (Fig 2B) .
As a result of the promising effects of MitoVitE observed in vitro we then went on to assess its effects in vivo, with duloxetine as comparator. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
In vivo studies
None of the treatments had an effect on weight gain (Supplementary file).There was also no effect of MitoVitE or duloxetine on withdrawal thresholds in the absence of paclitaxel administration, i.e. in naïve animals (see Supplementary file).
Mechanical withdrawal thresholds of a hind paw were examined, every second day, at 3, 6, and 9h after the daily injection of MitoVitE or duloxetine (Fig 3) . Rats receiving paclitaxel with vehicle control treatments had significantly lower withdrawal threshold values compared to those receiving Cremophor from 4 days following the first paclitaxel injection until the end of the study (day 14). Rats receiving paclitaxel plus duloxetine had significantly higher withdrawal threshold values than rats given paclitaxel plus vehicle control on days 8-12.
However rats receiving paclitaxel plus MitoVitE had significantly higher withdrawal threshold values than rats given paclitaxel plus vehicle control, over the longer timeframe of days [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] (with the exception of day 6).
For both MitoVitE and duloxetine treatment groups, significantly increased withdrawal thresholds were not consistent across the 3, 6 and 9h time points indicating time-dependent drug effects (Fig 3) . To directly assess this, area under the curve (AUC) values between days 0 and 14 were calculated for each individual animal at each time point (Fig 4A) . There was no significant difference between 3, 6 and 9h time points in the rats receiving either Cremophor or paclitaxel plus vehicle control. However in rats receiving paclitaxel plus duloxetine there was a significant effect of time, with a peak effect at 6h. In contrast, although there was a significant effect of time in the rats receiving paclitaxel plus MitoVitE there was a progressively increasing effect between 3 and 9h. This led us to assess an additional 24hr time point following the last drug/vehicle administration (day 14, Fig 4B) . There was a significant effect at the 6h time point only in rats treated with paclitaxel plus duloxetine, compared with rats given paclitaxel plus vehicle control. The effect was more prolonged in rats receiving paclitaxel plus MitoVitE with a significant effect at 6, 9 and 24h (Fig 4B) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 There was loss of mitochondrial membrane potential, reduced metabolic activity, and loss of glutathione. Co-treatment of cells with paclitaxel plus MitoVitE but not Trolox, protected against these effects. MitoVitE also did not decrease the ability of paclitaxel treatment to kill cancer cells in two different cancer cell lines, whilst cytotoxicity against breast cancer cells was decreased by Trolox. In a rat model of chemotherapy induced neuropathic pain, we also showed that MitoVitE decreased paclitaxel-induced mechanical hypersensitivity to a similar degree as duloxetine. Moreover, at the doses tested, the duration of action of MitoVitE was more prolonged than that of duloxetine.
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Chemotherapy remains the mainstay of cancer treatment for solid tumours but side effects can be severe enough to limit treatment. Paclitaxel acts by binding to microtubules and causing arrest of mitosis in cancer cells, followed by apoptotic cell death. Although proliferating cancer cells are susceptible to the action of paclitaxel, neuronal cells are also targets for damage and it has been shown that paclitaxel initiates opening of the mitochondrial permeability transition pore leading to loss of mitochondrial function in DRG cells. 21 In paclitaxel treated rats, neuropathic pain behaviour was shown previously to be associated with evidence of mitochondrial damage in peripheral nerves, 9 and administration of mitochondrial poisons such as rotenone was seen to worsen such behaviours.
22
The main function of mitochondria is to produce energy via oxidative phosphorylation but they are also an important source of ROS production, essential for signalling pathways.
Although excessive mitochondrial ROS can be detrimental, antioxidant systems work in synergy to control potential damage under normal conditions. 5 Exposure of a variety of cell types to paclitaxel has been shown to result in increased ROS production and oxidative stress 7 8 and in animals, treatment with spin trap global radical scavengers reduced pain behaviour induced by paclitaxel. 23 Recently, an inhibitor of mitochondrial p53 accumulation was reported to limit paclitaxel induced mitochondrial damage and prevented mechanical allodynia, supporting the mechanistic importance of mitochondrial dysfunction and the rationale for targeting treatment specifically at mitochondria.
24
Antioxidants can be modified to specifically target mitochondria and may be more effective than those that do not. MitoVitE is able to enter mitochondria by virtue of the TPP cationic conjugate which enables accumulation several hundred fold inside the mitochondrion relative to cytosolic levels. It has been shown to be many more times more effective at protecting against oxidative damage to mitochondria than other non-targeted antioxidants 10 11 and we and others have shown it to be effective in other disease models involving mitochondrial We used the well-characterized rat model of paclitaxel-induced neuropathic pain, where rats exhibit reduced mechanical withdrawal thresholds as assessed using Von Frey filaments, indicative of mechanical allodynia. 19 20 Several rat models of paclitaxel-induced CIPN exist, employing a wide range of doses, treatment regimens and routes of administration. The specific model used here is amongst the most widely used and best characterized of paclitaxel induced CIPN models. 19 We found, at the doses tested, treatment with MitoVitE (a mitochondria targeted form of tocopherol) limited paclitaxel-induced mechanical hypersensitivity to a similar level as that seen with duloxetine and moreover had a longer duration of action. Duloxetine has been shown to be effective in reducing neuropathic pain in clinical trials in patients treated with chemotherapy. 3 4 In rat models of neuropathy other than that induced by paclitaxel, tocopherol (naturally occurring lipid soluble vitamin E) was reported to reduce allodynia after sciatic nerve crush injury, 37 chronic constriction induced ischaemic injury 38 and oxalipatin induced neuropathy. 39 MitoVitE has been shown to be more effective in reducing mitochondrial damage in rat models of sepsis, another condition involving oxidative stress 25 26 but there have been no studies describing its use in neuropathy or pain.
MitoVitE has not been through Phase I trials and so cannot currently be used in patients;
however this study demonstrates proof of concept regarding a beneficial effect of mitochondria targeted antioxidant protection for CIPN. Other antioxidants which specifically protect inside mitochondria may be suitable for clinical use. 40 Further work should assess different antioxidant doses, varied timings of administration in relation to pain onset and any 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w potential synergy with duloxetine. It would also be of interest to study the impact on underlying neuropathology by quantifying intraepidermal nerve fibre density.
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41
In summary we showed that paclitaxel induced mitochondrial damage in dorsal root ganglion cells in vitro and that this was ameliorated by MitoVitE but not Trolox. In a rat model of paclitaxel induced neuropathic pain, MitoVitE was as effective at reducing mechanical hypersensitivity as duloxetine, the first line treatment for patients with paclitaxel induced neuropathic pain. These results confirm the role of mitochondrial oxidative damage in paclitaxel-mediated CIPN and suggest novel future treatment strategies . 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w LC: designed study, supervised conduct, and contributed to writing the paper.
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